| |  Online-Ressource |
|---|
| Verfasst von: | Töllner, Maximilian [VerfasserIn]  |
|---|
| | Speer, Claudius [VerfasserIn] |
|---|
| | Benning, Louise [VerfasserIn] |
|---|
| | Bartenschlager, Marie [VerfasserIn] |
|---|
| | Nußhag, Christian [VerfasserIn] |
|---|
| | Morath, Christian [VerfasserIn] |
|---|
| | Zeier, Martin [VerfasserIn] |
|---|
| | Süsal, Caner [VerfasserIn] |
|---|
| | Schnitzler, Paul [VerfasserIn] |
|---|
| | Schmitt, Wilhelm [VerfasserIn] |
|---|
| | Bergner, Raoul [VerfasserIn] |
|---|
| | Bartenschlager, Ralf [VerfasserIn] |
|---|
| | Lorenz, Hanns-Martin [VerfasserIn] |
|---|
| | Schaier, Matthias [VerfasserIn] |
|---|
| Titel: | Impaired neutralizing antibody activity against B.1.617.2 (delta) after anti-SARS-CoV-2 vaccination in patients receiving anti-CD20 therapy |
|---|
| Verf.angabe: | Maximilian Töllner, Claudius Speer, Louise Benning, Marie Bartenschlager, Christian Nusshag, Christian Morath, Martin Zeier, Caner Süsal, Paul Schnitzler, Wilhelm Schmitt, Raoul Bergner, Ralf Bartenschlager, Hanns-Martin Lorenz and Matthias Schaier |
|---|
| E-Jahr: | 2022 |
|---|
| Jahr: | 21 March 2022 |
|---|
| Umfang: | 16 S. |
|---|
| Fussnoten: | Gesehen am 02.07.2022 |
|---|
| Titel Quelle: | Enthalten in: Journal of Clinical Medicine |
|---|
| Ort Quelle: | Basel : MDPI, 2012 |
|---|
| Jahr Quelle: | 2022 |
|---|
| Band/Heft Quelle: | 11(2022), 6, Artikel-ID 1739, Seite 1-16 |
|---|
| ISSN Quelle: | 2077-0383 |
|---|
| Abstract: | Background: To characterize humoral response after standard anti-SARS-CoV-2 vaccination in Rituximab-treated patients and to determine the optimal time point after last Rituximab treatment for appropriate immunization. Methods: Sixty-four patients who received Rituximab within the last seven years prior to the first anti-SARS-CoV-2 vaccination were recruited in a prospective observational study. Anti-S1 IgG, SARS-CoV-2 specific neutralization, and various SARS-CoV-2 target antibodies were determined. A live virus assay was used to assess neutralizing antibody activity against B.1.617.2 (delta). In Rituximab-treated patients, CD19+ peripheral B-cells were quantified using flow cytometry. Results: After second vaccination, all antibodies were significantly reduced compared to healthy controls. Neutralizing antibody activity against B.1.617.2 (delta) was detectable with a median (IQR) ID50 of 0 (0-1:20) compared to 1:320 (1:160-1:320) in healthy controls (for all p < 0.001). Longer time period since last Rituximab administration correlated with higher anti-SARS-CoV-2 antibody levels and a stronger neutralization of B.1.617.2 (delta). With one exception, only patients with a CD19+ cell proportion ≥ 1% had detectable neutralizing antibodies. Conclusion: Our data indicate that a reconstitution of the B-cell population to >1% seems crucial in developing neutralizing antibodies against SARS-CoV-2. We suggest that anti-SARS-CoV-2 vaccination should be administered at least 8-12 months after the last Rituximab treatment for sufficient humoral responses. |
|---|
| DOI: | doi:10.3390/jcm11061739 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.3390/jcm11061739 |
|---|
| | Volltext: https://www.mdpi.com/2077-0383/11/6/1739 |
|---|
| | DOI: https://doi.org/10.3390/jcm11061739 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | COVID-19 |
|---|
| | Rituximab |
|---|
| | vaccination |
|---|
| K10plus-PPN: | 1808807294 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Impaired neutralizing antibody activity against B.1.617.2 (delta) after anti-SARS-CoV-2 vaccination in patients receiving anti-CD20 therapy / Töllner, Maximilian [VerfasserIn]; 21 March 2022 (Online-Ressource)
